We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNPR icon
76
Monopar Therapeutics
MNPR
$751M
$14.6M 0.27%
+157,423
New +$9.75M
TVTX icon
77
Travere Therapeutics
TVTX
$6.19B
$14.4M 0.27%
+253,000
New +$11.2M
TSHA icon
78
Taysha Gene Therapies
TSHA
$1.88B
$13.6M 0.25%
+2,000,000
New +$11.8M
BIIB icon
79
Biogen
BIIB
$32.3B
$13.3M 0.25%
61,600
– –
RVMD icon
80
Revolution Medicines
RVMD
$44.6B
$13.2M 0.24%
70,500
+18,500
+36% +$2.7M
DNTH icon
81
Dianthus Therapeutics
DNTH
$5.92B
$11.2M 0.21%
+115,000
New +$10M
SPRB
82
Spruce Biosciences
SPRB
$175M
$10.8M 0.2%
+200,000
New +$11.2M
LFST icon
83
Lifestance Health
LFST
$4.7B
$10.1M 0.19%
947,400
+447,400
+89% +$3.46M
RVMD icon
84
CALL
Revolution Medicines
RVMD
$44.6B
$9.36M 0.17%
+50,000
New +$7.3M
ERAS icon
85
Erasca
ERAS
$6.31B
$9.08M 0.17%
+495,900
New +$7.09M
TARA icon
86
Protara Therapeutics
TARA
$226M
$8.48M 0.16%
+2,220,000
New +$10.6M
KROS icon
87
Keros Therapeutics
KROS
$219M
$8.12M 0.15%
759,155
– –
JANX icon
88
Janux Therapeutics
JANX
$1.1B
$8.06M 0.15%
524,700
-458,900
-47% -$6.65M
TECX
89
Tectonic Therapeutic
TECX
$696M
$7.79M 0.14%
226,600
– –
ACET icon
90
Adicet Bio
ACET
$84.8M
$7.3M 0.14%
844,787
-183,157
-18% -$1.44M
PHVS icon
91
Pharvaris
PHVS
$2.48B
$7.1M 0.13%
205,400
– –
ANRO icon
92
Alto Neuroscience
ANRO
$1.38B
$6.8M 0.13%
257,852
+90,352
+54% +$2.09M
ZNTL icon
93
Zentalis Pharmaceuticals
ZNTL
$360M
$6.74M 0.13%
+1,390,576
New +$5.55M
DRUG
94
Bright Minds Biosciences
DRUG
$714M
$6.53M 0.12%
93,000
+53,000
+133% +$4.16M
PVLA
95
CALL
Palvella Therapeutics
PVLA
$2.16B
$6.11M 0.11%
40,000
-10,000
-20% -$1.21M
ALXO icon
96
ALX Oncology
ALXO
$277M
$5.93M 0.11%
2,866,256
– –
XLO icon
97
Xilio Therapeutics
XLO
$59.2M
$5.67M 0.11%
+592,300
New +$4.95M
BCAX
98
Bicara Therapeutics
BCAX
$1.55B
$5.67M 0.11%
191,100
-476,200
-71% -$10.6M
IMA
99
ImageneBio Inc
IMA
$60.6M
$5.36M 0.1%
909,269
+530,713
+140% +$3M
PTGX icon
100
Protagonist Therapeutics
PTGX
$9.34B
$5.16M 0.1%
42,100
– –
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.